|
Alexion Pharmaceuticals Inc (ALXN) |
|
|
|
ALXN's Capital Expenditures Growth by Quarter and Year
Alexion Pharmaceuticals Inc 's Capital Expenditures results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Capital Expenditures Growth Y/Y▼
|
Capital Expenditures Growth Y/Y▼
|
ALXN Capital Expenditures (in millions $) |
FY 2021 |
FY 2020 |
FY 2019 |
FY 2018 |
IV Quarter |
December |
-
|
77.50
|
30.00
|
42.40
|
III Quarter |
September |
-
|
10.80
|
49.90
|
41.20
|
II Quarter |
June |
-
|
6.20
|
46.80
|
62.80
|
I Quarter |
March |
130.20
|
12.20
|
44.00
|
66.60
|
FY |
|
130.20
|
106.70
|
170.70
|
213.00
|
ALXN Capital Expenditures first quarter 2021 Y/Y Growth Comment |
Alexion Pharmaceuticals Inc showed record Capital Expenditures surge in the first quarter 2021 with 967.21% from the first quarter 2021 2020, to $ 130.20 millions.
Looking into first quarter 2021 results within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Capital Expenditures growth. While Alexion Pharmaceuticals Inc ' s Capital Expenditures doubling of 967.21% ranks overall at the positon no. 116 in the first quarter 2021.
|
ALXN Capital Expenditures ( Y/Y Growth %) |
2021
|
2020 |
2019 |
2018 |
IV Quarter |
December |
- |
158.33 % |
-29.25 % |
-51.98 % |
III Quarter |
September |
- |
-78.36 % |
21.12 % |
-56.17 % |
II Quarter |
June |
- |
-86.75 % |
-25.48 % |
-37.2 % |
I Quarter |
March |
967.21 % |
-72.27 % |
-33.93 % |
-11.2 % |
FY |
|
- |
-37.49 % |
-19.86 % |
-40.39 % |
ALXN Capital Expenditures (Quarter on Quarter Growth %) |
2021
|
2020 |
2019 |
2018 |
IV Quarter |
December |
- |
617.59 % |
-39.88 % |
2.91 % |
III Quarter |
September |
- |
74.19 % |
6.62 % |
-34.39 % |
II Quarter |
June |
- |
-49.18 % |
6.36 % |
-5.71 % |
I Quarter |
March |
68 % |
-59.33 % |
3.77 % |
-24.58 % |
FY (Year on Year) |
|
- |
-37.49 % |
-19.86 % |
-40.39 % |
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
967.21 % |
100.13 % |
-86.75 % |
(Mar 31 2021) |
|
(Jun 30 2020) |
|
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
967.21 % |
100.13 % |
-86.75 % |
(Mar 31 2021) |
|
(Jun 30 2020) |
|
Capital Expenditures by Quarter for the Fiscal Years 2018, 2019, 2020, 2021 |
Alexion Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
617.59 % |
32.78 % |
-59.33 % |
(Dec 31 2020) |
|
|
ALXN's I. Quarter Q/Q Capital Expenditures Comment |
Alexion Pharmaceuticals Inc achieved in the I. Quarter 2021 above company average sequential Capital Expenditures jump of 68%, to $ 130.20 millions, from $77.50 millions in the fourth quarter.
Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Alexion Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 538. |
|
|
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
617.59 % |
32.78 % |
-59.33 % |
(Dec 31 2020) |
|
|
ALXN's I. Quarter Q/Q Capital Expenditures Comment |
Alexion Pharmaceuticals Inc achieved in the I. Quarter 2021 above company average sequential Capital Expenditures jump of 68%, to $ 130.20 millions, from $77.50 millions in the fourth quarter.
Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Alexion Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 538. |
|
Alexion Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year
Capital Expenditures TTM Growth |
12 Months Ending (Mar 31 2021) |
12 Months Ending (Dec 31 2020) |
12 Months Ending (Sep 30 2020) |
12 Months Ending (Jun 30 2020) |
12 Months Ending (Mar 31 2020) |
Cumulative Capital Expenditures 12 Months Ending |
$ 224.70 |
$ 106.70 |
$ 59.20 |
$ 98.30 |
$ 138.90 |
Y / Y Capital Expenditures Growth (TTM) |
61.77 % |
-37.49 % |
-67.67 % |
-43.64 % |
-27.05 % |
Year on Year Capital Expenditures Growth Overall
Ranking |
# 1856 |
# 300 |
# 2712 |
# 2295 |
# 2333 |
Seqeuential Capital Expenditures Change (TTM) |
110.59 % |
80.24 % |
-39.78 % |
-29.23 % |
-18.63 % |
Seq. Capital Expenditures Growth (TTM) Overall
Ranking |
# 1653 |
# 160 |
# 2903 |
# 382 |
# 1429 |
Cumulative Capital Expenditures growth
Comment |
Alexion Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 61.77% year on year, to $ 225 millions if the fiscal year would have ended in Mar 31 2021. Alexion Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 51.34% and higher than -37.49% growth in Dec 31 2020. The growth was much higher from twelve months ended Dec 31 2020 clinched at 110.59 % rise from $106.7 millions in twelve months ending a quarter before.
In the Healthcare sector 323 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 300 to 1856. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
365.92 % |
51.34 % |
-67.67 % |
|
|
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
365.92 % |
51.34 % |
-67.67 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 113 |
Sector |
# 304 |
S&P 500 |
# 1653 |
|
Cumulative Capital Expenditures growth
Comment |
Alexion Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 61.77% year on year, to $ 225 millions if the fiscal year would have ended in Mar 31 2021. Alexion Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 51.34% and higher than -37.49% growth in Dec 31 2020. The progress was much stronger sequentially exhibited at 110.59 % increase from $106.7 millions in the period from Dec 31 2020 to Mar 31 2020.
In the Healthcare sector 323 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 300 to 1856. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
365.92 % |
51.34 % |
-67.67 % |
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
365.92 % |
51.34 % |
-67.67 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 113 |
Sector |
# 304 |
S&P 500 |
# 1653 |
Companies with similar Capital Expenditures jump for the quarter ending Mar 31 2021 within Healthcare Sector | Y/Y Change % | Capital Expenditures for the quarter ending Mar 31 2021 | Arcus Biosciences Inc | 1,642.11% | $ 1,642.105 millions | Iovance Biotherapeutics Inc | 1,580.53% | $ 1,580.534 millions | Xeris Biopharma Holdings Inc | 1,550.00% | $ 1,550.000 millions | Enveric Biosciences Inc | 1,456.23% | $ 1,456.232 millions | Y mabs Therapeutics inc | 1,438.46% | $ 1,438.462 millions | Imunon Inc | 1,437.30% | $ 1,437.304 millions | Fulgent Genetics Inc | 1,343.72% | $ 1,343.719 millions | Zentalis Pharmaceuticals Inc | 1,306.45% | $ 1,306.452 millions | Arcutis Biotherapeutics Inc | 1,251.22% | $ 1,251.220 millions | Quidelortho Corp | 1,230.57% | $ 1,230.574 millions | Passage Bio inc | 1,214.14% | $ 1,214.141 millions | Otonomy Inc | 1,200.00% | $ 1,200.000 millions | Constellation Pharmaceuticals Inc | 1,189.47% | $ 1,189.474 millions | Chemocentryx Inc. | 1,153.46% | $ 1,153.456 millions | Chinook Therapeutics Inc | 1,137.50% | $ 1,137.500 millions | Predictive Oncology Inc | 1,109.23% | $ 1,109.231 millions | Nighthawk Biosciences inc | 1,086.30% | $ 1,086.296 millions | Biolife Solutions Inc | 1,078.08% | $ 1,078.082 millions | Aytu Biopharma Inc | 1,040.65% | $ 1,040.646 millions | Scholar Rock Holding Corp | 1,006.22% | $ 1,006.220 millions | Chimerix Inc | 971.43% | $ 971.429 millions | Alexion Pharmaceuticals Inc | 967.21% | $ 967.213 millions | Ibio inc | 959.38% | $ 959.375 millions | Neurogene Inc | 917.76% | $ 917.757 millions | Lftd Partners Inc | 882.94% | $ 882.940 millions | Immunovant Inc | 850.00% | $ 850.000 millions | Sintx Technologies Inc | 809.52% | $ 809.524 millions | Imac Holdings Inc | 808.04% | $ 808.035 millions | Harpoon Therapeutics Inc | 800.00% | $ 800.000 millions | Meridian Bioscience Inc | 720.37% | $ 720.366 millions |
|